Cargando…
Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children
BACKGROUND AND OBJECTIVE: Spinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by insufficient levels of survival motor neuron (SMN) protein. Risdiplam (Evrysdi(TM)) increases SMN protein and is approved for the treatment of SMA. Risdiplam has high oral bioavailability and is...
Autores principales: | Cleary, Yumi, Kletzl, Heidemarie, Grimsey, Paul, Heinig, Katja, Ogungbenro, Kayode, Silber Baumann, Hanna Elisabeth, Frey, Nicolas, Aarons, Leon, Galetin, Aleksandra, Gertz, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256639/ https://www.ncbi.nlm.nih.gov/pubmed/37148485 http://dx.doi.org/10.1007/s40262-023-01241-7 |
Ejemplares similares
-
Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
por: Cleary, Yumi, et al.
Publicado: (2021) -
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
por: Kletzl, Heidemarie, et al.
Publicado: (2022) -
Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation
por: Barnett, Shelby, et al.
Publicado: (2018) -
A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
por: Yau, Estelle, et al.
Publicado: (2023) -
Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
por: Chiriboga, Claudia A., et al.
Publicado: (2023)